AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENTSecurities Purchase Agreement and Registration Rights Agreement • August 7th, 2013 • Ascent Solar Technologies, Inc. • Semiconductors & related devices • Delaware
This Amendment No. 1 to Securities Purchase Agreement and Registration Rights Agreement (“Amendment”) is made and entered into as of August 7, 2013 (“Effective Date”), by and between Ascent Solar Technologies, Inc., a Delaware corporation (“Company”), and Seng Wei Seow (“Purchaser”).
AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT Authentidate Holding Corp. and certain of the Purchasers to the Securities Purchase Agreement dated as of May 29, 2015Securities Purchase Agreement and Registration Rights Agreement • November 13th, 2015 • Authentidate Holding Corp • Services-computer integrated systems design • New York
This Amendment No. 2 to the Securities Purchase Agreement and Registration Rights Agreement is effective as of the 25th day of September, 2015 (the “Second Amendment Agreement”), and is made by and among Authentidate Holding Corp., a Delaware corporation (the “Company”) and those persons and entities executing the signature pages to this Second Amendment Agreement (the “Purchasers”).
FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENTSecurities Purchase Agreement and Registration Rights Agreement • August 2nd, 2010 • Aradigm Corp • Electromedical & electrotherapeutic apparatus • New York
This FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT, dated as of July 20, 2010 (this “First Amendment”), is by and among Aradigm Corporation, a California corporation with offices located at 3929 Point Eden Way, Hayward, CA 94545 (the “Company”), and the undersigned investors.
Idera Pharmaceuticals, Inc. AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENTSecurities Purchase Agreement and Registration Rights Agreement • December 15th, 2020 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amendment to the Prior SPA and the Prior RRA (each as defined below) effective as of December 11, 2020, is made by and between Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Pillar Partners Foundation, L.P., a Cayman Islands limited partnership (“Pillar Foundation”) and Pillar Pharmaceuticals 6, L.P., a Cayman Islands limited partnership (“Pillar 6” and, together with Pillar Foundation, the “Purchasers”). Unless otherwise defined herein, capitalized terms shall have the meanings assigned to such terms in the Prior SPA (as defined below).
FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENTSecurities Purchase Agreement and Registration Rights Agreement • August 14th, 2023 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
This Frist Amendment to Securities Purchase Agreement and Registration Rights Agreement (the “Agreement”) is entered into this 8th day of October, 2021, by and between Allarity Therapeutics, Inc., a Delaware corporation with offices located at 210 Broadway, Ste 201, Cambridge, MA 02139 (the “Company”), Allarity Therapeutics A/S, a Danish public limited company located at Venlighedsvej 1, 2970 Horsholm, Denmark (the “Parent”) and 3i, LP, a Delaware limited partnership with offices located at 140 Broadway, 38th Floor New York, NY 10005 (the “Buyer” and collectively with the Company and the Parent, the “Parties” and each a “Party”).
joint amendment TO SECURITIES PURCHASE AGREEMENT and registration rights agreementSecurities Purchase Agreement and Registration Rights Agreement • April 11th, 2013 • Arno Therapeutics, Inc • Pharmaceutical preparations
This Joint Amendment (the “Amendment”) is entered into as of March 25, 2013, by and between Arno Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned Purchasers.
Joint AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT and registration rights agreementSecurities Purchase Agreement and Registration Rights Agreement • October 30th, 2013 • Arno Therapeutics, Inc • Pharmaceutical preparations
This Joint Amendment No. 2 (the “Amendment”) is entered into as of October 29, 2013, by and between Arno Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned Purchasers.
AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENTSecurities Purchase Agreement and Registration Rights Agreement • June 17th, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is made and entered into as of June 16, 2005, by and among Generex Biotechnology Corporation, a Delaware corporation (“Generex”), and the stockholders identified on the signature pages hereto (each, a “Purchaser” and, collectively, the “Purchasers”).
AMENDMENT NO. 3 TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENTSecurities Purchase Agreement and Registration Rights Agreement • December 5th, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This AMENDMENT NO. 3 TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is made and entered into as of December 4, 2005, by and among Generex Biotechnology Corporation, a Delaware corporation (“Generex”), and the stockholders identified on the signature pages hereto (each, a “Purchaser” and, collectively, the “Purchasers”).
AMENDMENT NO. 4 TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENTSecurities Purchase Agreement and Registration Rights Agreement • January 20th, 2006 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This AMENDMENT NO. 4 TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is made and entered into as of January 19, 2006, by and among Generex Biotechnology Corporation, a Delaware corporation (“Generex”), and the stockholders identified on the signature pages hereto (each, a “Purchaser” and, collectively, the “Purchasers”).
AMENDMENT TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENTSecurities Purchase Agreement and Registration Rights Agreement • February 10th, 2010 • Worldwide Energy & Manufacturing Usa Inc • Miscellaneous manufacturing industries
This Amendment (the “Amendment”), dated as of February 9, 2010, is made to the Securities Purchase Agreement, dated as of January 26, 2010 (the “Purchase Agreement”), between Worldwide Energy and Manufacturing USA, Inc., a Colorado corporation (the “Company”) and the purchasers identified on the signatures pages thereto (the “Holders”), and to the Registration Rights Agreement, dated as of January 26, 2010 (the “Registration Rights Agreement”), between the Company and the Holders. Terms used as defined terms herein and not otherwise defined shall have the meanings provided therefor in the Purchase Agreement.
AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT By and Among Authentidate Holding Corp. and certain of the Purchasers to the Securities Purchase Agreement dated as of May 29, 2015Securities Purchase Agreement and Registration Rights Agreement • October 13th, 2015 • Authentidate Holding Corp • Services-computer integrated systems design • New York
This Amendment No. 1 to the Securities Purchase Agreement, and Registration Rights Agreement is effective as of the 7th day of July 2015 (the “Amendment Agreement”), and is made by and among Authentidate Holding Corp., a Delaware corporation (the “Company”) and those persons and entities executing the signature pages to this Amendment Agreement (the “Purchasers”).
AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENTSecurities Purchase Agreement and Registration Rights Agreement • September 9th, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is made and entered into as of September 8, 2005, by and among Generex Biotechnology Corporation, a Delaware corporation (“Generex”), and the stockholders identified on the signature pages hereto (each, a “Purchaser” and, collectively, the “Purchasers”).
